Tags

Type your tag names separated by a space and hit enter

Neuraminidase inhibitors for treatment of influenza A and B infections.
MMWR Recomm Rep. 1999 Dec 17; 48(RR-14):1-9.MR

Abstract

Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at <http://www.cdc.gov/ncidod/diseases/flu/ fluvirus.htm> or at the MMWR website at <http://www2.cdc.gov/mmwr/>.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10632443

Citation

"Neuraminidase Inhibitors for Treatment of Influenza a and B Infections." MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports, vol. 48, no. RR-14, 1999, pp. 1-9.
Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep. 1999;48(RR-14):1-9.
(1999). Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports, 48(RR-14), 1-9.
Neuraminidase Inhibitors for Treatment of Influenza a and B Infections. MMWR Recomm Rep. 1999 Dec 17;48(RR-14):1-9. PubMed PMID: 10632443.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuraminidase inhibitors for treatment of influenza A and B infections. PY - 2000/1/13/pubmed PY - 2000/2/19/medline PY - 2000/1/13/entrez SP - 1 EP - 9 JF - MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports JO - MMWR Recomm Rep VL - 48 IS - RR-14 N2 - Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at <http://www.cdc.gov/ncidod/diseases/flu/ fluvirus.htm> or at the MMWR website at <http://www2.cdc.gov/mmwr/>. SN - 1057-5987 UR - https://www.unboundmedicine.com/medline/citation/10632443/Neuraminidase_inhibitors_for_treatment_of_influenza_A_and_B_infections_ L2 - http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4814a1.htm DB - PRIME DP - Unbound Medicine ER -